

Electronic Supplementary Material (ESM) file #1

Manuscript title: Genomic testing for relapsed and refractory Lymphoid Cancers: Understanding patient values

Journal Name: The Patient

Author names: Sarah Costa¹, Dean A Regier^{1,2}, Adam JN Raymakers^{1,3}, & Samantha Pollard^{1*}

1. Canadian Centre for Applied Research in Cancer Control, BC Cancer – Vancouver, Canada
2. School of Population and Public Health, University of British Columbia – Vancouver, Canada
3. Faculty of Health Sciences, Simon Fraser University – Vancouver, Canada

Affiliation and e-mail address of the corresponding author: Samantha Pollard (spollard@bccrc.ca), Canadian Centre for Applied Research in Cancer Control, BC Cancer – Vancouver, Canada

Electronic supplementary material – Slide deck presented at focus group sessions

Understanding your preferences

Focus Group Session

Why are we all here today?

- **Gene testing**
- **Relapse**
- **Decision-making**

Our research question

What is important **to you** about the use of **gene information** for **relapse** care?


When might a gene test be used?

1. To help select the most effective treatment for the disease


Usual care



DNA




After gene testing




When might a gene test be used?

1. To help select the most effective treatment for the disease
2. To provide more information about the disease


Before gene testing




Information about prognosis




Making decisions about gene testing





Making decisions about gene testing



Things to consider



- Types of test procedures



In summary, gene testing...

- Provides **information** about the cancer
- **May or may not** lead to changes in treatment
- Has other **considerations** that may influence your decision

What are your thoughts?

What is important **to you** about the use of **gene information** for **relapse** care?